Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The Phase I trial is evaluating safety, tolerability, pharmacokinetics and preliminary efficacy of MBS8(1V270) in subjects with advanced solid tumours. The trial is designed to provide data for further clinical development of MBS8(1V270)
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznanie zaawansowanego nowotworu litego z postępem choroby, bez dostępnego standardowego leczenia lub jego odmowy
- •Dostęp do guza do wykonania biopsji
- •Możliwość regularnego uczestnictwa w wizycie, leczeniu, badaniach krwi i biopsji
- •Mierzalne ogniska nowotworu
- •Dobry ogólny stan zdrowia (skala ECOG 0-1)
- •Oczekiwana długość życia ponad 3 miesiące
- •Prawidłowe wyniki badań krwi, nerek i wątroby
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
Herlev and Gentofte Hospital, Center for Cancer Research
Herlev, Denmark
Institut Catalá de Oncologia - Hospital Duran i Reynals.
Barcelona, Spain
Fundacion Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (FJD)
Madrid, Spain
Centro Integral Oncológico Clara Campal (CIOCC)
Madrid, Spain
Consorcio Hospital General Universitario de Valencia
Valencia, Spain
Trial contact
Simon S Jensen, PhD
Steven Glazer, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.